Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase III, Randomized, Double-Blind, Placebo-Controlled Study of SU011248 in the Treatment of Patients With Imatinib Mesylate (Gleevec, Glivec)-Resistant or Intolerant Malignant Gastrointestinal Stromal Tumor.

X
Trial Profile

A Phase III, Randomized, Double-Blind, Placebo-Controlled Study of SU011248 in the Treatment of Patients With Imatinib Mesylate (Gleevec, Glivec)-Resistant or Intolerant Malignant Gastrointestinal Stromal Tumor.

Status: Completed
Phase of Trial: Phase III

Latest Information Update: 25 Jun 2020

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Sunitinib (Primary)
  • Indications Gastrointestinal stromal tumours
  • Focus Registrational; Therapeutic Use
  • Most Recent Events

    • 10 Jun 2020 Results (n=350) of simulation study from four clinical trials: study 1004, study 1047, study 1045 and study 013 assessing effects of dose increase on pharmacodynamic biomarkers can increase OS and retaining an acceptable safety profile published in the Clinical Cancer Research
    • 29 Sep 2009 Actual end date changed from 10 Oct 2006 to 1 May 2008 as reported by ClinicalTrials.gov (NCT00075218).
    • 29 Sep 2009 Actual end date changed from 10 Oct 2006 to 1 May 2008 as reported by ClinicalTrials.gov (NCT00075218).
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top